ALMS (Alumis) Total Long-Term Liabilities : $32.53 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Alumis Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Alumis's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was $32.53 Mil.

Alumis Total Long-Term Liabilities Historical Data

The historical data trend for Alumis's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Total Long-Term Liabilities Chart

Alumis Annual Data

Trend

Dec22

Dec23

Dec24

Total Long-Term Liabilities

290.06

408.00

29.98

Alumis Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial					539.31	670.52	30.66	29.98	32.53

Alumis Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Alumis Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Alumis's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alumis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

280 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alumis.com

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.